Announced details
Research on medical countermeasures (MCM) for infectious disease emergencies, including vaccines, therapeutics and diagnostics, and infectious disease research
Our company will participate in cSIMVa as a partner company. Capital and personnel relationships are Not disclosed.
The university that hosts the Future Mucosal Vaccine Research and Development Synergy Center (cSIMVa). Location, representative, capital and year established are Not disclosed.
Chiba University (detailed location: Not disclosed)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Reference information on the Japan Agency for Medical Research and Development (AMED), and reference information on Chiba University Future Mucosal Vaccine Research and Development Synergy Center (cSIMVa)
| Item | Details |
|---|---|
| Names of Products / Services Covered | Chiba University Future Mucosal Vaccine Research and Development Synergy Center (cSIMVa) |
| Counterparty | National University Corporation Chiba University |
| Counterparty overview | The university that hosts the Future Mucosal Vaccine Research and Development Synergy Center (cSIMVa). Location, representative, capital and year established are Not disclosed. |
| Relationship with the Company | Our company will participate in cSIMVa as a partner company. Capital and personnel relationships are Not disclosed. |
| Launch date | As of the announcement on 6 October 2026, participation is newly planned (specific start date: Not disclosed). |
| Applicable area | Research on medical countermeasures (MCM) for infectious disease emergencies, including vaccines, therapeutics and diagnostics, and infectious disease research |
| Location | Chiba University (detailed location: Not disclosed) |
| Source | Reference information on the Japan Agency for Medical Research and Development (AMED), and reference information on Chiba University Future Mucosal Vaccine Research and Development Synergy Center (cSIMVa) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To deepen collaboration with Chiba University and the companies participating in this project, create research and business opportunities in new infectious disease fields by applying the technologies and expertise cultivated through antibody drug discovery, and contribute during infectious disease emergencies.